Reaction Biology Announces New Epigenetic Production Facilities
News Apr 26, 2012
"The new facility expands our space by over 50%, and gives us the ability to greatly expand our production of epigenetic related proteins," remarked Dr. Haiching Ma, RBC Chief Technology Officer. "We will be able to accelerate growth of our list of available targets, and add space for new collaborations."
RBC simultaneously announced that it has expanded its available list of methyltransferase and related proteins to 27, and is continuing to add more. A number of the proteins are exclusive to RBC and cannot be found elsewhere. RBC now offers 25 HMT/DNMT's, including all of the human members of the important MLL/SET1 family of multi-protein complexes, along with 11 HDAC's, 4 SIRT's, 7 HAT's, and 12 DUB's.
The field of epigenetics is rapidly becoming the new focus of the drug-discovery and pharmaceutical industry. Epigenetic targets modulate gene expression, and have been indicated in a wide variety of diseases and conditions including cancer, inflammation, metabolic and neuropsychiatric diseases.
"The ability to selectively control gene expression is a holy grail for drug researchers. Drugs that successfully inhibit HMT or DNMT targets could be hugely effective," said Dr. Konrad Howitz, RBC Director of Epigenetics. "With the largest panel of such targets and proprietary high-quality proteins, we believe RBC could play a central role in this new research."
Easily Automate PK Assays for Human IgG Drugs in Preclinical SpeciesNews
At AAPS NBC event, Lumigen produced a poster summarizing the use of their pipetting robot, Andrew which can measure IgG drug concentration in a pre-clinical setting.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017